ENZC Company Profile and Key Details

Average 10-day trading volume of 5.35 million shares is slightly above the 3-month average of 3.84 million, indicating heightened recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Enzolytics Inc. trades at a P/E ratio of -9.34, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -0.01 indicating negative book value, which may reflect financial stress. The P/FCF stands at 0.0, also above market averages.

Our AI price prediction model suggests that Enzolytics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows Enzolytics Inc. trading at a premium to the broader market with a P/E of -9.34.

The stock is currently mid-range between its 52-week high and low $0.00 and $0.00. With a market capitalization of about $1.93 million, Enzolytics Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.51). Key stats such as the average daily volume over the past year has been around 4.06 million shares, volume is running light vs its 52-week average. Headquartered in Plano, TX, Enzolytics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steven Sharabura, the company employs approximately 1 people and listed since April 08, 2009. Enzolytics Inc., a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies.